Takeshi Fukumoto

Dr. Takeshi Fukumoto

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
AFAtsushi Fukunaga
Atsushi Fukunaga
YOYoshiko Oda
Yoshiko Oda
SIShinya Imamura
Shinya Imamura
MMMayuko Mizuno
Mayuko Mizuno
TFTakeshi Fukumoto
Takeshi Fukumoto
KWKen Washio
Ken Washio

25 February 2021 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
TFTakeshi Fukumoto
Takeshi Fukumoto
RFRie Fukumoto
Rie Fukumoto
EMElizabeth Magno
Elizabeth Magno
MOMasahiro Oka
Masahiro Oka
CNChikako Nishigori
Chikako Nishigori
NHNobuyuki Horita
Nobuyuki Horita
Existing guidelines form no consensus for alopecia areata (AA) treatment due to the absence of a universal standard treatment and arbitrary selection of reference arms in randomized control trials (RCTs). The aim is to identify the best treatment and to rank treatments using systematic review and network meta‐analysis. Data were extracted by the two investigators independently. Odds ratio (OR) of treatment success rate was pooled using the frequentist weighted least squares approach to random‐model network meta‐analysis. RCTs providing data of treatment success rate from PubMed, EMBASE, Web of Science, and manual search were included. About 54 RCTs consisting of 49 treatments and 3149 patients were included. Pentoxifylline plus topical corticosteroids had the highest treatment success rate compared with “no treatment,” followed by pentoxifylline alone, topical calcipotriol plus narrowband ultraviolet radiation B phototherapy, topical calcipotriol, intralesional corticosteroids, systemic corticosteroids, minoxidil plus topical corticosteroids, topical bimatoprost, psoralen ultraviolet radiation A phototherapy, and tofacitinib. Even with the network meta‐analysis, the best treatment because of independent loops and wide confidence intervals could not be identified. Treatment options above may be reasonable strategies, but further comparison is required.

1 June 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
TFTakeshi Fukumoto
Takeshi Fukumoto
JLJianhuang Lin
Jianhuang Lin
NFNail Fatkhutdinov
Nail Fatkhutdinov
PLPingyu Liu
Pingyu Liu
RSRajasekharan Somasundaram
Rajasekharan Somasundaram
CNChikako Nishigori
Chikako Nishigori

15 February 2024 in The Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
XWXuebing Wang
Xuebing Wang
TFTakeshi Fukumoto
Takeshi Fukumoto
KNKen-Ichi Noma
Ken-Ichi Noma
Cellular senescence occurs in response to endogenous or exogenous stresses and is characterized by stable cell cycle arrest, alterations in nuclear morphology and secretion of proinflammatory factors, referred to as the senescence-associated secretory phenotype (SASP). An increase of senescent cells is associated with the development of several types of cancer and aging-related diseases. Therefore, senolytic agents that selectively remove senescent cells may offer opportunities for developing new therapeutic strategies against such cancers and aging-related diseases. This review outlines senescence inducers and the general characteristics of senescent cells. We also discuss the involvement of senescent cells in certain cancers and diseases. Finally, we describe a series of senolytic agents and their utilization in therapeutic strategies.

2 January 2020 in Modern Rheumatology
Verified
Journal Article
Closed access
HKHiroaki Kato
Hiroaki Kato
MTMasaki Takeuchi
Masaki Takeuchi
Nobuyuki HoritaNobuyuki Horita
Nobuyuki Horita
TITakehito Ishido
Takehito Ishido
RMRyuta Mizuki
Ryuta Mizuki
NMNobuhisa Mizuki
Nobuhisa Mizuki
Background: How HLA-A26 modulates Behçet’s disease ocular lesions such as iridocyclitis and retinochorioiditis has not been scrutinized. Methods: Ministry of Health, Labour and Welfare of Japan provided us a database of Behçet’s disease patients who were registered from 2003 to 2014. We selected patients who satisfied International Criteria for Behçet’s Disease and whose data for HLA-A26 was available. Results. Eligible 557 patients consisting of 238 men (42.7%) and 319 women (57.3%), whose median age was 38 years old (interquartile range (IQR) 29-47) were analyzed. Prevalence of general ocular lesions, iridocyclitis, retinochorioiditis, and chronic lesions were 43.1%, 30.7%, 34.1%, and 17.4%, respectively. The prevalence of ocular lesions was higher among HLA-A26 carriers compared to that among HLA-A26 non-carriers with odds ratio (OR) of 2.5 (95% confidence interval (95% CI) 1.8-3.5, P < 0.001) for general ocular lesions, OR of 2.5 (95% CI 1.7-3.6, P < 0.001) for iridocyclitis, OR of 2.8 (95% CI 1.9-4.0, P < 0.001) for retinochorioiditis, and OR of 2.7 (95% CI 1.7-4.3, P < 0.001) for “chronic ocular lesion following iridocyclitis or retinochorioiditis.” The HLA-A26 had a similar impact on ocular lesions between HLA-B51 positive and negative cases (Breslow-Day test, P > 0.05). However, the HLA-A26 had a larger impact on iridocyclitis for men compared to women (Breslow-Day test, P = 0.040). The male HLA-A26 carriers had higher risk of iridocyclitis with OR of 3.4 (95%CI 2.0-5.9, P <0.001), while the OR for women was 1.5 (95%CI 0.9-2.6, P = 0.146). Conclusion: HLA-A26 carriers had higher risk for iridocyclitis and retinochorioiditis. However, the impact was more prominent for men.

1 April 2018 in Plastic and Reconstructive Surgery - Global Open
Verified
Journal Article
Open access
TITakanori Iwayama
Takanori Iwayama
KHKazunobu Hashikawa
Kazunobu Hashikawa
TOTakeo Osaki
Takeo Osaki
KYKenjiro Yamashiro
Kenjiro Yamashiro
NHNobuyuki Horita
Nobuyuki Horita
TFTakeshi Fukumoto
Takeshi Fukumoto
Summary: Hyaluronic acid (HA) is present in the connective tissues of the skin and decreases with age. HA fillers are popular as facial rejuvenation treatments. They are generally considered safe; however, complications, such as cutaneous necrosis and blindness due to vascular embolism, sometimes occur. Because vascular embolisms are likely associated with the deep placement of HA fillers, a strategy that involves injection into superficial regions (the conventional method) is commonly used to reduce risks. However, deep injections to achieve revolumization are becoming common, even in high-risk areas for intravascular infusion. We aimed to study the usefulness of the ultrasonography-guided cannula method for preventing intravascular infusion of HA fillers. An HA filler was injected into the region just under the dermis on the left side of the face of a 38-year-old man using the conventional method, and another HA filler was injected into the periosteum on the right side using the ultrasonography-guided cannula method. The skin blood flow on both sides was compared using laser speckle flowgraphy (LSFG). The ultrasonography-guided method was successful in detecting the cannula and the blood vessel, and the HA filler was safely injected into a deep region. Using LSFG, a difference in skin blood flow between the 2 methods was detected. The ultrasonography-guided cannula method was effective in aiding the safe injection of an HA filler in a deep high-risk area and maintained skin blood flow. LSFG may be adopted to evaluate skin blood flow after HA filler injections.